Close
Leave blank for all. Otherwise, the first selected term will be the default instead of "Any".

Sarbanes Oxley 404(b) recommendations made by the 2009 Government-Business Forum on Small Business Capital Formation

Mar 10 2016

...

IFRS Roadmap: SEC requests comments on U.S. conversion to a set of global accounting standards

Mar 10 2016
BIO provides comment letter to SEC generally supporting the IFRS roadmap while maintaining safeguards for emerging companies during transition.

Letter to the Honorable John Carey

Mar 10 2016
Letter to the Honorable John Carey, Chairman of the Senate Committee on Finance and Financial Institutions in Ohio from BIO, regarding House Bill 66.

Letter to Governor Deval Patrick

Mar 10 2016
BIO letter to Governor Deval Patrick of Massachusetts regarding concerns about Senate Bill 2863.

BIO Testimony regarding Oregan Senate Bill 570

Mar 10 2016
Testimony to the Oregon Senate Environment & Land Use Committee regarding The Oregon Genetically Engineered Pharmaceutical and Industrial Crop Act.

Questions for the District of Columbia Board of Pharmacy for the drafting of SafeRx

Mar 10 2016
Frequently Asked Questions Document

Clinical Trials: ICTRP guidelines

Mar 10 2016
BIO urges the ICTRP to focus on developing a procedure that would address the need to balance the incentive to innovate with the need to provide patients and health care providers with the information they need in order to assess the availability and suitability of a clinical trial.

Clinical Trials: Review of the Declaration of Helsinki

Mar 10 2016
BIO’s comments on the World Medical Association’s (WMA’s) Declaration of Helsinki.

Request for Comment Extension RE: Docket No. APHIS-2014-0054 – Environmental Impact Statement; Introduction of the Products of Biotechnology

Feb 18 2016
We, the undersigned organizations, appreciate the opportunity to provide comment on APHIS’ Notice of Intent (NOI) to prepare an environmental impact statement in connection with potential changes to APHIS biotechnology regulations (7 CFR 340). Our member organizations represent a broad cross-section of stakeholders having a significant interest in the future of U.S. agriculture, including farmers, grower groups, handlers, marketers, processors, manufacturers, distributors and exporters of agricultural products, as well as seed companies and technology providers.

BIO 2016 Special 301 Submission

Feb 8 2016
The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the 2016 Special 301 Submission.